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Editorial on the Research Topic
The Molecular Mechanisms of Cyclic AMP in Regulation of Immunity and Tolerance
The inhibitory effects of the second messenger cyclic adenosine monophosphate (cAMP) on T-cell 
proliferation and effector functions have been originally reported by Gary Kammer in 1988 (1). At 
that time, little had been known about the mechanisms by which the inhibitory effects occur. The 
situation changed upon the discovery of the hallmark of cAMP responsive transcription—cAMP-
responsive element binding (CREB) protein by Jim Hoeffler in Joel Habener’s lab at Massachusetts 
General Hospital (Boston, MA, USA) (2). However, it was still unclear how stimulation of the cAMP-
dependent signaling pathway could exert an inhibitory effect on T-cell proliferation and effector 
functions. Soon after joining Joel Habener’s lab, I started to collaborate with Anna-Lena Spetz in 
Jack Strominger’s lab at the Dana-Farber Cancer Institute (Boston, MA, USA). Anna-Lena provided 
human thymus glands obtained from children undergoing corrective heart surgery and fractionated 
them over discontinuous Percoll gradients in order to separate medullary from cortical thymocytes. 
Our analyses confirmed that cAMP-dependent signaling is likely to play an important role during 
intrathymic T cell development since unexpectedly high intracellular levels of cAMP were formed in 
more mature medullary thymocytes in the presence of forskolin or prostaglandin E2. This ability to 
generate cAMP correlated with the expression of the potent transcriptional repressor ICER (inducible 
cAMP early repressor) and was retained by the majority of mature peripheral blood T lymphocytes 
(3). Induction of ICER was claimed to be exclusive to hypothalamic–pituitary–gonadal axis by Paolo 
Sassone-Corsi (4); however, our discovery of robust ICER expression in the human immune system 
came as a surprise (3). At the same time, Jeff Leiden demonstrated that thymocytes transgenic for 
a dominant negative isoform of CREB (DN CREB) were unable to phosphorylate the critical Ser at 
position 119 displayed after T cell activation. This functional defect resulted in a profound prolifera-
tive consequence characterized by markedly decreased interleukin-2 (IL-2) production (5). Clearly, 
a single point mutation of the critical Ser119 disabled activation domain in DN CREB acted to a 
similar extent as ICER, which lacks this activation domain entirely, and thus served as dominant 
negative repressor of IL-2 expression [note added in proof (3)]. Soon afterward, Ron Schwartz at the 
National Institutes of Health (Bethesda, MD, USA) redefined T cell anergy as failure to produce IL-2 
via CREB/CREM-mediated transcriptional attenuation (6). Since ICER represents the only cAMP 
responsive subfamily of four isoforms (4), we concluded that at least part of inhibitory effects of 
cAMP on IL-2 production and T cell proliferation are due to exploitation of molecular mechanisms 
based on ICER induction and its high affinity binding at the CD28-responsive element (CD28RE) 
(7, 8). Since ICER does not possess a transactivation domain required for the recruitment of CREB 
binding protein (CBP)/p300, the binding of ICER to CD28RE and/or composite motifs containing 
CRE-like recognition sequences may also lead to uncoupling of CBP/p300, thus extinguishing IL-2 
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expression as well as expression of numerous other cytokines 
and chemokines driven by nuclear factor of activated T cells 
(NFAT) (9). Once T cell anergy had been redefined, Marc Gavin 
in Alexander Rudensky’s lab proposed another role for cAMP 
(and cAMP-induced ICER) in “anergy” of naturally occurring 
regulatory CD4+CD25+ T cells (nTregs) (10). He proposed that 
high intracellular levels of cAMP were maintained in nTregs by 
Foxp3-mediated repression of phosphodiesterase 3b, an enzyme 
responsible for cAMP degradation (11). This raised further ques-
tions, e.g., whether cAMP and ICER could play a role in nTreg 
cell-mediated suppression of IL-2 in CD4+ conventional T cells 
(Tcons). When I met Shimon Sakaguchi at the meeting in Boston, 
we discussed this possibility and he invited me to pursue this topic 
in his lab at Kyoto University in Japan. This resulted in a fruitful 
collaboration with Zoltan Fehervari who was already in Shimon’s 
lab at that time. During my stay in Shimon’s lab, Zoltan and myself 
proved that ICER/CREM in responder Tcons were definitively 
involved in nTreg cell-mediated suppression (12). Moreover, in 
discussion with Anjana Rao, we postulated the potential role of an 
inhibitory NFAT/ICER complex in Tcons as a means for induc-
tion of tolerance conveyed by nTreg cells. Meanwhile, Tobias 
Bopp in Edgar Schmitt’s lab at Uni-Mainz (Germany) reported 
cAMP as a key component of nTreg cell-mediated suppression 
(13). Tobias showed that transfer of the high intracellular cAMP 
levels accumulated in nTreg cells is critically involved in contact-
dependent suppression of Tcons via intercellular gap junctions. 
To test this hypothesis, I joined Edgar Serfling’s lab in Wuerzburg 
(Germany), and in collaboration with Martin Vaeth, we per-
formed confocal analyses of nTregs (14). Using two mouse mod-
els, we demonstrated that nTreg cells induced via cAMP a nuclear 
localization of ICER in Tcons and thereby inhibited their IL-2 
synthesis. Ablation of nTreg cells using diphtheria toxin-mediated 
depletion of regulatory T-cells in DEpletion of REGulatory T cells 
mice resulted in cytosolic localization of ICER and increased IL-2 
synthesis upon stimulation in vivo (14). Thus, upon stimulation 
with a CD28-superagonistic monoclonal antibody (15), direct 
contacts between nTreg cells and Tcons led to cAMP-dependent 
induction and nuclear accumulation of ICER and suppression 
of IL-2 synthesis in Tcons as hypothesized previously (14). We 
presumed that a close interaction of ICER and NFAT bound to 
the IL-2 promoter in Tcons is of vital importance for the nTreg 
cell-mediated suppression. Therefore, we attempted to crystallize 
the NFAT/ICER complex in cooperation with Caroline Kisker at 
Uni-Wuerzburg, and soon, we obtained crystals. Unfortunately, 
their analyses showed that despite expectations they did not con-
tain all the components in the complex. Meanwhile, Anjana Rao 
together with Lin Chen crystallized the NFAT/Foxp3 complex 
and claimed this complex to be central to tolerance conveyed 
by nTreg cells (16). However, this work was flawed by two major 
problems: (i) they did not use Foxp3 but Foxp2 (a gene with 
function quite distinct from Foxp3) and (ii) nTreg cells do not 
translocate NFAT efficiently to the nucleus, a finding reported by 
us (14) and others (17). In conclusion, convincing proof of the 
existence of a molecular complex central to immune tolerance 
(NFAT/ICER or NFAT/FoxP3) remains elusive and awaits further 
investigation.
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